Drug major GlaxoSmithKline (GSK) has unethically tested a breast cancer drug on poor patients in India for approval for new drugs in the Europe Union, said a study. According to an investigation by Mumbai-based Centre for Studies in Ethics and Rights, the firm tested lapatinib on patients flouting Indian Council of Medical Research's (ICMR) ethical guidelines.This trial required seriously ill patients who had not received treatment for their condition.
read more
The Translational Genomics Research Institute (TGen), Scottsdale Healthcare and Mayo Clinic are testing a new drug that could help cancer patients by stimulating the immune system. Clinical trials of the drug VTX-2337 are being cond... Read Post
GlaxoSmithKline (NYSE: GSK) provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of CERVARIX(R), its vaccine to prevent cervical cancer. GSK has submitted its response t... Read Post
GlaxoSmithKline on Wednesday applied for approval to market its breast cancer drug Tykerb in U.S. and Europe as a first-line treatment for women with advanced, hormone-sensitive breast cancer, the AP/Google.com reports. Tykerb, know... Read Post